Our studies further provide evidence for potential intervention and modulation of muscle atrophy by cPLA2 pathway inhibition that could be relevant for sarcopenia and other diseases of muscle wasting including ALS and nerve injury. This evidence concerns the gene PLA2G4A and injury.